MX2022015806A - Agente profilactico o terapeutico para la fotodermatosis. - Google Patents

Agente profilactico o terapeutico para la fotodermatosis.

Info

Publication number
MX2022015806A
MX2022015806A MX2022015806A MX2022015806A MX2022015806A MX 2022015806 A MX2022015806 A MX 2022015806A MX 2022015806 A MX2022015806 A MX 2022015806A MX 2022015806 A MX2022015806 A MX 2022015806A MX 2022015806 A MX2022015806 A MX 2022015806A
Authority
MX
Mexico
Prior art keywords
skin disease
preventive
therapeutic agent
actinic skin
excluding
Prior art date
Application number
MX2022015806A
Other languages
English (en)
Inventor
Tsuyoshi Suzuki
Masahiro Kondo
Yuko Kawano
Atsuhiro Matsumoto
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX2022015806A publication Critical patent/MX2022015806A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un medicamento para tratar o prevenir una condición que es tratable o prevenible mediante la promoción de la producción de melanina, tal como fotodermatosis (excluyendo la porfiria), enfermedad hipopigmentaria (excluyendo el vitiligo vulgar), efectos adversos de la fototerapia o pelo canoso, dicho medicamento comprendiendo un compuesto representado por la fórmula general [I], (ver Fórmula) o una sal o cocristal farmacéuticamente aceptable del mismo, como ingrediente activo.
MX2022015806A 2020-06-10 2021-06-10 Agente profilactico o terapeutico para la fotodermatosis. MX2022015806A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020101162 2020-06-10
PCT/JP2021/022048 WO2021251452A1 (ja) 2020-06-10 2021-06-10 光線性皮膚疾患の予防又は治療剤

Publications (1)

Publication Number Publication Date
MX2022015806A true MX2022015806A (es) 2023-03-21

Family

ID=78846115

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015806A MX2022015806A (es) 2020-06-10 2021-06-10 Agente profilactico o terapeutico para la fotodermatosis.

Country Status (13)

Country Link
US (1) US20230226034A1 (es)
EP (1) EP4166139A4 (es)
JP (1) JPWO2021251452A1 (es)
KR (1) KR20230016008A (es)
CN (2) CN115768428A (es)
AR (1) AR122595A1 (es)
AU (2) AU2021289054B2 (es)
BR (1) BR112022025115A2 (es)
CA (1) CA3186882A1 (es)
IL (1) IL298951A (es)
MX (1) MX2022015806A (es)
TW (1) TW202214240A (es)
WO (1) WO2021251452A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024009413A (es) * 2022-01-31 2024-08-14 Mitsubishi Tanabe Pharma Corp Novedoso uso del agonista del receptor de melanocortina-1.
WO2024029599A1 (ja) * 2022-08-03 2024-02-08 田辺三菱製薬株式会社 １－｛２－［（３ｓ，４ｒ）－１－｛［（３ｒ，４ｒ）－１－シクロペンチル－３－フルオロ－４－（４－メトキシフェニル）ピロリジン－３－イル］カルボニル｝－４－（メトキシメチル）ピロリジン－３－イル］－５－（トリフルオロメチル）フェニル｝ピペリジン－４－カルボン酸もしくはその医薬的に許容し得る塩又は共結晶を含有する医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2865422B1 (en) 2006-08-31 2017-10-18 Clinuvel Pharmaceuticals Limited Alpha-MSH derivatives for the treatment of photodermatoses
WO2009103816A1 (en) 2008-02-22 2009-08-27 Clinuvel Pharmaceuticals Limited Method for treatment of photosensitivity and phototoxicity
FR2981933B1 (fr) * 2011-11-02 2013-11-15 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
EP2925340B8 (en) * 2012-11-21 2019-07-24 University Of Cincinnati Pharmaceutical compositions comprising selective agonists of melanocortin 1 receptor and their use in therapeutic methods
US20140271742A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Skin tanning using peptides and other compositions
WO2015067503A1 (en) 2013-11-07 2015-05-14 Clinuvel Ag Alpha-msh analogues for use in the treatment of psoriasis
US9981960B2 (en) 2014-05-29 2018-05-29 Mitsubishi Tanabe Pharma Corporation Pyrrolidine compound and application as melanocortin receptor agonist
JP6392297B2 (ja) * 2015-11-27 2018-09-19 田辺三菱製薬株式会社 医薬組成物
CA3050630A1 (en) 2017-02-01 2018-08-09 Clinuvel Pharmaceuticals Ltd Alpha-msh analogues used in the treatment of xeroderma pigmentosum
CN113226314A (zh) 2018-12-28 2021-08-06 田边三菱制药株式会社 吡咯烷化合物的晶体

Also Published As

Publication number Publication date
EP4166139A1 (en) 2023-04-19
IL298951A (en) 2023-02-01
BR112022025115A2 (pt) 2023-02-07
WO2021251452A1 (ja) 2021-12-16
AU2021289054B2 (en) 2024-03-21
AU2021289054A1 (en) 2023-02-02
CN115768428A (zh) 2023-03-07
AU2024203990A1 (en) 2024-07-04
JPWO2021251452A1 (es) 2021-12-16
AR122595A1 (es) 2022-09-21
TW202214240A (zh) 2022-04-16
CA3186882A1 (en) 2021-12-16
KR20230016008A (ko) 2023-01-31
US20230226034A1 (en) 2023-07-20
EP4166139A4 (en) 2024-06-26
CN118453598A (zh) 2024-08-09

Similar Documents

Publication Publication Date Title
MX2022015806A (es) Agente profilactico o terapeutico para la fotodermatosis.
HK1120441A1 (en) Drugs for treatment of ovarian cancer
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
MX2023003627A (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer.
IL143579A0 (en) Erythropoietin derivatives for the treatment of cerebral ischemia
WO2008020027A3 (en) 2,5-dihydroxybenzene compounds for the treatment of skin cancer
MX2023003564A (es) Compuestos y su uso en el tratamiento del cancer.
MX2024001777A (es) Derivado de sulfonamida, metodo de preparacion y uso medico del mismo.
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
MX2022015531A (es) Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo.
WO2021146536A8 (en) Therapeutic agents and methods of treatment
BR0307588A (pt) Composto, inibidor de gsk-3, composição farmacêutica, e, agente terapêutico ou preventivo para uma doença
MX2024004846A (es) Compuesto tetraciclico que contiene nitrogeno, metodo de preparacion del mismo y uso medico del mismo.
EP2292226A3 (en) The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin
CL2022000639A1 (es) Métodos de uso para activadores de canal kv7
WO2014001215A3 (en) 3-o-heteroaryl-ingenol
MX2022003845A (es) Tratamientos cognitivos medicinales.
MX2013006128A (es) Nuevo compuesto y uso medico del mismo.
MX2022008216A (es) Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo.
MX2011011529A (es) Uso de alopurinol para el tratamiento de la reaccion cutanea en manos-pies.
WO2022159028A3 (en) Method of treating a skin disorder by administering an amiloride derivative
MX2023003569A (es) Tratamiento de padecimientos dermatologicos.
MX2022008148A (es) Inhibidores de btk.